Poly-MVA – A New Cancer Breakthrough for advanced cancer patients
Written by Lisa Marie Wark*
If you or a loved one has been diagnosed with cancer, Poly-MVA therapy might be your best alternative.
It’s not conventional cancer therapy. Nor is it chemotherapy or even immunotherapy. It’s a patented food supplement that is taking center stage in the battle against cancer.
Could something as simple as a dietary food supplement really help in treating advanced cancer patients? Medical oncologist and homeopathic physician, Dr. James W. Forsythe is hopeful. Dr. Forsythe has been conducting a Poly-MVA outcome based investigation on various Stage IV Cancers since January of 2004 in Reno, Nevada and has seen encouraging results. “We have seen patients go into full remission with aggressive, stage IV cancers and we see continued positive responses in others with previously chemo-resistant cancer. Other benefits from Poly-MVA are a significantly improved quality of life and a substantial reduction in the number and severity of side effects from chemo and radiation therapies.”
What you need to know about Poly-MVA
Poly-MVA has been around for about ten years and hundreds of doctors are prescribing it in various countries. It is a uniquely formulated combination of vitamins, minerals and amino acids. In 1991, the patented supplement was invented by Dr. Merill Garnett.
Cancer cells are anaerobic, or cells that require very little oxygen in order to function and reproduce. Dr. Garnett’s cancer cell approach relied on the theory that cancer cells thrive on simple sugars and like low oxygen environments for their metabolism. Based on that theory, he developed a product that would interfere with the metabolism process in the cancer cell. Garnett combined palladium with lipoic acid, B-12 and thiamine which created an extremely useful and safe cellular nutrient. These combined ingredients promote energy production and offer potent antioxidant protection at the cellular level. When administered to advanced cancer patients, Poly-MVA appears to have the unique capacity to negatively affect anaerobic cells while supporting healthy tissues. Simply put, this nutrient attacks the “engine room” of a cancer cell and short circuits the cell’s energy production thereby destroying it.
Why palladium? Palladium has unique properties that help it combine well with alpha lipoic acid which is an extremely strong antioxidant. The idea of combining a rare metal with an antioxidant came to Garnett because he thought it would interfere with the electron transfer in the cancer cell. It would affect the part of the cancer cell metabolism which is the anaerobic side of cancer metabolism. This complex is a key part of the Poly-MVA food supplement.
Because Poly-MVA is nontoxic and natural, side effects are minimal. Dr. Forsythe is happy to report the few side effects. “Taking the supplement intravenously, I have seen a small percentage of patients who have reported a chill and/or a low grade fever. This is easily remedied by slowing down the drip or by giving an antihistamine to mitigate any possible allergic reaction.
As far as nausea, vomiting or diarrhea, these are uncommon side effects, diarrhea probably being more common than the other two. There is no hair loss, no skin rashes, no cytopenias or lowering of white count and red count cells. And we’ve seen no damage to any major organ systems such as the heart, liver, pancreas, or sexual organs.” In fact, according to his study, the Poly-MVA not only helps the healthy cells but it has shown to be synergistic with chemotherapy, enhancing the effects of it. “Because it is an energizer, it does make patients feel better. Perhaps they feel able to better tolerate the chemo better.”
Dr. Forsythe’s Poly-MVA Clinical Results
To date, 160 patients are involved in the investigation. The patients are classified into two groups. The first group is administered both the Poly-MVA and chemotherapy. The other group, who refused chemotherapy were on the supplement only. In both groups, the Poly-MVA dosage is administered intravenously for a fifteen day period. The patient is then switched to an oral dosage which could take it up to six to eight months. After six months a maintenance dosage is administered depending upon the remission of the tumor. Because this is an ongoing clinical study, there is no charge for the supplement, but there is a small administrative fee.
The study group that used both chemotherapy and Poly-MVA were treated with low doses of chemotherapy. “My approach to treating cancer uses a lower dose fractionated chemo or “dose dense” chemo where you’re getting it more often but in lower doses. So you’re getting either the same amount or more chemo but its spread out so it’s less toxic to the patient. My patients have less toxicity than patients who receive the ‘sledgehammer approach’ which is to really hit the patient hard with chemo every three-four weeks. The sledgehammer chemo patients often have severe toxicities from the chemo.”
The Poly-MVA clinical results: a 70 percent response rate which included partial remission and complete remission responses in the group that received both the chemotherapy and Poly-MVA supplement and a 42 percent response rate from the group who received the supplement exclusively. (Partial reduction means a 50 percent reduction in the size of the tumor mass and complete reduction means a disappearance of the disease resulting from a physical examination, scanning and tumor markers.)
After participating in this investigation, both groups expressed having more physical energy. Dr. Forsythe attributes their energy and optimism to Poly-MVA being a natural substance. “Because they are on a protocol with a natural substance they seem to be doing better mentally and physically. Their approach to chemo, their optimism, their ability to fight the cancer is improved. I think it does a lot for their mental attitude. It does empower the patient in that they feel as if they are doing more than the average patient is doing in their fight against cancer.”
Dr. Forsythe’s patients who have participated in the Poly-MVA clinical investigation are also optimistic. Marilyn Haro-Smith who is suffering from inoperable lung cancer and was told she had only three to six months to live, has seen encouraging results from the Poly-MVA.“During the past five years I have been treated by Dr. Forsythe with both low-dose fractionated chemotherapy and alternative therapies. One year ago my cancer markers were going up and Dr. Forsythe placed me on his clinical out-come based protocol with Poly-MVA. Since then, this natural supplement has stabilized my disease and normalized my markers.”
Michael Oliver who has been battling prostate cancer tells his story. “My PSA began to rise one year ago and Dr. Forsythe placed me on his clinical investigation with oral Poly-MVA and since this time my PSA has been near normal and I have not required any chemotherapy. I have had no side-affects from the Poly-MVA. I feel better and have more energy.”
The top three cancers that were highly responsive to the Poly-MVA treatment were prostate, breast and non-small cell lung cancer. Surprisingly non-small cell lunge cancer is, in general, not a high responder to conventional treatments. Colorectal cancers were the least responsive.
Dr. James Forsythe’s investigation is the largest of the current studies and includes the treatment of all types of cancers. Dr Forsythe’s clinical investigation is in cooperation with University of New York at Stony Brook and is affiliated with the University of Nevada, Reno. Dr Forsythe is as an Associate Professor of Alternative Medicine at the University of Nevada, Reno.
CONTACT HEALTHY REFERRAL 866-99-GRAND TO ORDER!
*Lisa Marie Wark is currently a free lance writer and is a business development consultant with a concentration in medical spas and alternative clinics. Currently she is President of MedSpas, <http://www.medspas.com/>www.MedSpas.com, a business development firm that provides physicians the necessary business tools to help them build or expand their practices into medical spa facilities. Wark was formerly an anchor and financial reporter for ON24 Financial News in San Francisco. In 2001, she was promoted to the main female anchor of three financial news broadcasts, covering a broad range of financial sectors and industries.
Wark’s hard work and persistence helped her land interviews with top executives from Fortune 500 companies that included the likes of Steve Forbes, former Republican Presidential candidate and Publisher of Forbes Magazine; Robert L. Crandall former American Airlines CEO who pioneered the first frequent flier mileage program AAdvantage; and Marc Andreesen, an Internet pioneer and creator of the Netscape browser.